A
Apollo Therapeutics
Advancing a pipeline of potentially transformative therapeutic programs based on breakthrough discoveries
About Apollo Therapeutics
Apollo Therapeutics is a startup that operates in the pharmaceutical industry, specifically in the area of drug development. The company's primary business model revolves around creating a portfolio of drugs at scale in a capital-efficient manner. This means that they aim to develop multiple drugs simultaneously while keeping costs low, which is a unique approach in the industry.
Read full description
Apollo Therapeutics serves a broad range of clients, including healthcare providers, pharmaceutical companies, and potentially patients who require the drugs they develop. Their market is global, given the universal need for effective and affordable medications.
The company makes money by developing drugs and then selling them to healthcare providers or pharmaceutical companies. They may also generate revenue through partnerships or licensing agreements with other companies that wish to produce and sell the drugs they develop.
In terms of financial analysis, Apollo Therapeutics' capital-efficient model could potentially offer high returns. By developing multiple drugs at once, they increase the chances of producing a successful product. Furthermore, by keeping costs low, any revenue generated can result in significant profit.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Stevenage, United Kingdom
- Employees
- 64
- Open positions
- None listed
- Dealroom signal
- 77.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Digital Therapeutics, Rumoured $1B, DT and LS, uk is8 life sciences, UKSU, UKSU2010, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Apollo Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Dec 2023 | $260M | $1B | Rock Springs Capital · M&G · Patient Square Capital | ↗ |
| SERIES BOther financing | Jun 2021 | $145M | $580M | Rock Springs Capital · Reimagined Ventures · UCL Technology Fund · AlbionVC | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Apollo Therapeutics is 5.1K monthly website visits, down 1.9% over the last three months. Apollo Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
AstraZeneca
GSK
Series A5 investors entered at this stage
Patient Square Capital
Rock Springs Capital
Reimagined Ventures
UCL Technology Fund
AlbionVC
Series B and later1 investor entered at this stage
M&G
Other known investors3 additional known investors
Cambridge Enterprise
University College London
University of Cambridge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Apollo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Apollo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.